Global Attention Deficit Hyperactivity Disorder Treatment- Drivers
Increasing prevalence of attention deficit hyperactivity disorder is expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, according to the study titled ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups’ published in the Journal of the American Medical Association (JAMA Network), in September, 2022, the total number of newly diagnosed patients with ADHD were 838,265 between the year 2010 to 2019. While 121,278 individuals were diagnosed at age of 0 to 6 years in Japan.
Furthermore, key companies focusing on research and development for the treatment of attention deficit hyperactivity disorder are expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.
Global Attention Deficit Hyperactivity Disorder Treatment: Restraint
The major factors that hinder growth of the global attention deficit hyperactivity disorder treatment market include high cost of attention deficit hyperactivity disorder drugs. Costs of attention deficit hyperactivity disorder drugs are quite high as these need research and development process, and their manufacturing is a very complex process, which needs highly skilled scientists. Such expensive biopharmaceutical drugs and medications are not affordable to organizations and hospitals such a Morris Foundation, education and health foundation (AMF) offering assessment and remedial educational assistance to students with Specific Learning Disabilities (SLDs) and Attention Deficit Hyperactivity Disorder (ADHD), India, in emerging economies such as India, China, etc. High cost of attention deficit hyperactivity disorder medication is a major factor hindering its adoption. For instance, in February 2022, a paper was published by National Center for Biotechnology Information, according to which from the year 2010 to 2019 sampled prescription for ADHD medications increased from US$ 125.29 to US$ 529.36 in China. Thus it was concluded that ADHD drugs and the corresponding increase in cost is increasing rapidly
Attention Deficit Hyperactivity Disorder Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients